Cumberland Pharmaceuticals Inc. (CPIX)

Market Cap	85.70M +3.6%
Revenue (ttm)	41.94M +2.1%
Net Income	-7.38M
EPS	-0.50
Shares Out	14.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,397
Open	5.70
Previous Close	5.72
Day's Range	5.46 - 5.75
52-Week Range	1.85 - 6.61
Beta	0.10
Analysts	Strong Buy
Price Target	8.50 (+48.6%)
Earnings Date	Aug 4, 2026

About CPIX

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sod...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Aug 11, 2009
• Employees: 93
• Stock Exchange: NASDAQ
• Ticker Symbol: CPIX
• Website: https://www.cumberlandpharma.com

Financial Performance

In 2025, CPIX's revenue was $44.52 million, an increase of 17.57% compared to the previous year's $37.87 million. Losses were -$2.84 million, -56.23% less than in 2024.

Analyst Summary

According to one analyst, the rating for CPIX stock is "Strong Buy" and the 12-month stock price target is $8.5.

Price Target

$8.5

(48.60% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jun 22, 2026

Data Sources Report a data error